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Sheng-Chia Chung, Rolf Gedeborg, Owen Nicholas, Stefan James, Anders Jeppsson, Charles Wolfe, Peter Heuschmann, Lars Wallentin, John Deanfi eld, 
Adam Timmis, Tomas Jernberg, Harry Hemingway
Summary 
Background International research for acute myocardial infarction lacks comparisons of whole health systems. We 
assessed time trends for care and outcomes in Sweden and the UK.
Methods We used data from national registries on consecutive patients registered between 2004 and 2010 in all hospitals 
providing care for acute coronary syndrome in Sweden and the UK. The primary outcome was all-cause mortality 30 days 
after admission. We compared eff ectiveness of treatment by indirect casemix standardisation. This study is registered 
with ClinicalTrials.gov, number NCT01359033.
Findings We assessed data for 119 786 patients in Sweden and 391 077 in the UK. 30-day mortality was 7·6% (95% CI 
7·4–7·7) in Sweden and 10·5% (10·4–10·6) in the UK. Mortality was higher in the UK in clinically relevant subgroups 
defi ned by troponin concentration, ST-segment elevation, age, sex, heart rate, systolic blood pressure, diabetes mellitus 
status, and smoking status. In Sweden, compared with the UK, there was earlier and more extensive uptake of primary 
percutaneous coronary intervention (59% vs 22%) and more frequent use of β blockers at discharge (89% vs 78%). After 
casemix standardisation the 30-day mortality ratio for UK versus Sweden was 1·37 (95% CI 1·30–1·45), which 
corresponds to 11 263 (95% CI 9620–12 827) excess deaths, but did decline over time (from 1·47, 95% CI 1·38–1·58 in 
2004 to 1·20, 1·12–1·29 in 2010; p=0·01).
Interpretation We found clinically important diff erences between countries in acute myocardial infarction care and 
outcomes. International comparisons research might help to improve health systems and prevent deaths.
Funding Seventh Framework Programme for Research, National Institute for Health Research, Wellcome Trust (UK), 
Swedish Association of Local Authorities and Regions, Swedish Heart-Lung Foundation.
Introduction
Recognition is growing of the need for comparative 
eff ectiveness research to improve the quality and outcomes 
of health care. International comparisons of cancer 
survival1 and years of life lost to ischaemic heart 
disease2 from 1990–2010 suggest that the performance of 
the UK health system needs to be improved. However, 
studies that simultaneously examine care and outcomes 
are lacking. The Institute of Medicine identifi ed health-
care delivery systems and cardio vascular care as among 
the highest priorities for comparative eff ectiveness 
research.3 The effi  cacy of treatments for acute myocardial 
infarction has been extensively studied in randomised 
trials,4,5 but uptake and use of these treatments vary within 
and between the UK (England and Wales) and Sweden.6–10 A 
study in patients with ST-segment-elevation myocardial 
infarction (STEMI) in 12 European countries reported 
increasing use of primary percutaneous coronary 
intervention (PCI) but showed striking diff erences 
between countries.11 Attributes of care systems, including 
organisational culture, care pathways, and programmes to 
improve quality, are not assessed in trials but might be 
associated with outcome.12 30-day mortality for acute 
myocardial infarction is an important indicator of hospital 
performance, and delivery of care has more immediate 
potential to improve outcomes than treatment 
innovations.13 International comparisons of whole health-
care delivery systems, therefore, might yield important, 
actionable insights to guide development of policies and 
clinical practice.14
International comparative eff ectiveness research for 
acute myocardial infarction has had three main limitations. 
First is a lack of comparison of whole health systems. 
Existing studies lack population coverage because they are 
based on selected samples of hospital patients reported in 
voluntary registries,8–10 one-off  surveys,15 or trials16 that are 
known to diff er from the national population in treatments 
and outcomes.17 Second, international studies have 
compared only care8 or outcomes18 or have been restricted 
to patients with either STEMI7–9 or non-STEMI.10 Third, 
attempts have not been made to standardise the mortality 
of patients in one country by the casemix in another. As a 
result, there are few studies between health systems from 
which to set benchmark outcome goals.
A crucial feature of the health systems in Sweden and 
the UK is that they are the only two countries worldwide 
that have continuous national clinical registries for acute 
coronary syndrome with mandated participation for all 
hospitals.19,20 Comparison of these two countries is 
facilitated by the similarity of their health systems 
(universal, funded from taxation, and free at the point of 
use), proportion of gross domestic product spent on 
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health, and national policy guidance provided for the 
evidence-based management of acute myocardial 
infarction.21,22 Diff erences are that Sweden has more rapid 
diff usion of some new technologies,23 more complete use 
of evidence-based practice,9 and a more established 
system for evaluating and reporting the quality and 
outcomes of care24 than the UK.
In the absence of previous international comparisons, 
our objectives in this study were as follows: fi rst, to assess 
the validity of comparing data from the two nationwide 
clinical registries; second, to compare time trends for 
proportions of patients in receipt of eff ective interventions 
while in hospital and at discharge between 2004 and 2010; 
third, to compare crude and casemix-standardised 30-day 
mortality between the two countries and between clinically 
important subgroups; fourth to estimate time trends in 
casemix-standardised mortality and compare them 
between Sweden and the UK; and fi fth, to explore the 
contribution of clinical care to any diff erence in mortality.
Methods
Study population
All hospitals providing care for acute myocardial infarction 
in Sweden and the UK contribute data on consecutive 
patients to the Swedish Web-System for Enhancement 
and Development of Evidence-Based Care in Heart 
Disease Evaluated According to Recommended Therapies 
(SWEDEHEART)/Register of Information and Knowledge 
about Swedish Heart Intensive care Admissions (RIKS-
HIA) and the UK Myocardial Ischaemia National Audit 
Project (MINAP), respectively. RIKS-HIA and MINAP 
comply with the Cardiology Audit and Registration Data 
Standards (for acute coronary syndrome in Europe.7,25,26 We 
obtained data for all patients who were admitted to 
hospital because of acute myocardial infarction between 
Jan 1, 2004, and Dec 31, 2010. For patients with multiple 
admissions we used the earliest record. Acute myocardial 
infarction diagnosis was based on guidelines from the 
European Society of Cardiology/American College of 
Cardiology/American Heart Association.27 The study was 
approved by the MINAP Academic Group and the steering 
group of SWEDEHEART.
Casemix and treatment measures
The defi nitions of casemix, evidence-based hospital 
treatment, and discharge medications in SWEDEHEART/
RIKS-HIA and MINAP were compared (appendix 
pp 2–9). The 17 casemix characteristics were demographic 
factors (age, sex, year of admission), risk factors (smoking, 
history of diabetes mellitus, and hypertension), severity of 
acute myocardial infarction (troponin concentrations, 
systolic blood pressure at admission, heart rate at 
admission), history of heart failure, cardiac arrest at 
admission, history of cerebrovascular disease, or history 
of acute myocardial infarction, and previous procedures 
or use of medication (antiplatelet treatment with aspirin, 
clopidogrel, or both, PCI, coronary artery bypass graft 
surgery). Features of hospital treatment for STEMI were 
reperfusion therapy (primary PCI or fi brinolytic therapy 
before or during hospital stay), delay between symptom 
onset and primary PCI or fi brinolysis, coronary 
intervention other than primary PCI, intravenous 
glycoprotein IIb/IIIa inhibitors, and use of anticoagulants. 
Discharge medications assessed were antiplatelet therapy 
(aspirin, clopidogrel, or both), β blockers, angiotensin-
converting-enzyme (ACE) inhibitors or angiotensin-
receptor blockers (ARBs), and statins. Validation of 
SWEDEHEART/RIKS-HIA (each year a trained monitor 
compares data with a chart review in 30 randomly selected 
patients within each hospital) showed a 96·1% 
agreement.20 Validation of MINAP data (compared with 
reaudit data, generated from each hospital annually by 
the re-entering of 20 data items on 20 randomly selected 
patients) showed a median agreement of 89·5%.19
Mortality
The primary clinical outcome was all-cause mortality 
within 30 days after hospital admission. National unique 
identifi ers were used to link patients with the National 
Death Registry in Sweden or the Offi  ce for National 
Statistics in the UK. We accessed these registries to 
ascertain vital status or date of death at 30 days.
Statistical analysis
We compared troponin I and T concentrations, casemix, 
hospital treatment, and medication at discharge between 
Swedish and UK patients. Data are shown as proportion 
(95% CI) for categorical variables and mean (SD) or 
median (IQR) for continuous variables. To further 
investigate the comparability of acute myocardial infarction 
See Online for appendix
All hospitals providing AMI care 
Sweden 86, UK 242
Admission records from all hospitals 
Sweden 414 831, UK 739 828
Study population of AMI patients 
Sweden 119 786, UK 391 077
Deaths at 30 days 
Sweden 9173, UK 41 509
Sweden/UK excluded 276 147/330 175 
ineligible records 
   5162/6998 age <30 years or missing
   266 787/73 031 non-AMI diagnosis
   0/126 916 admitted before or after 
   inclusion dates
   4198/123 230 did not meet other 
   demographic criteria
18 898/18 576 subsequent admissions
Figure 1: Study population
AMI=acute myocardial infarction. ID=identifi er.
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diagnosis in the two registries, we compared the propensity 
of acute myocardial infarction diagnosis between UK and 
Sweden patients (appendix pp 12–13). Treatments for acute 
myocardial infarction were also compared by year of 
hospital admission.
We compared mortality outcomes with Kaplan-Meier 
analysis in clinically important subgroups (STEMI or non-
STEMI, troponin concentration, systolic blood pressure at 
admission, heart rate at admission, sex, age, year of 
admission, diabetes status, and smoking), after casemix 
standardisation, and by propensity-score matching. In 
casemix standardisation, we modelled 30-day mortality for 
the two countries with the 17 casemix variables then 
applied the Sweden model to the UK acute myocardial 
infarction population to estimate the casemix-standardised 
relative risk of observed UK 30-day mortality for each study 
year and overall. In propensity matching, we estimated the 
propensity of being a STEMI patient and the propensity of 
being a non-STEMI patient in Sweden and the UK, 
according to logistic regression, and then matched patients 
on the basis of propensity scores (appendix pp 12–14).
Casemix models incorporated a random eff ect for 
participant hospital. The extent of missing values was 
assessed and then managed by multiple imputation 
(appendix pp 16–19). Analyses were performed with SAS 
(version 9.3), R (version 2.9.2), and Matlab (version 7.14). 
This study is registered with ClinicalTrials.gov, number 
NCT01359033.
Role of the funding source
The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. S-CC had full access to all the data in the study. 
TJ and HH had fi nal responsibility for the decision to 
submit for publication.
Results
The study population was drawn from 86 hospitals in 
Sweden and 242 in the UK. 119 786 patients were eligible in 
Sweden and 391 077 in the UK (fi gure 1) and data on 30-day 
mortality were available for 119 786 (100%) and 390 951 
(99·97%) of these, respectively.
Median concentrations (IQR) maximum troponin I and 
troponin T were similar in Sweden and the UK overall 
(table 1) and for STEMI and non-STEMI patients by year 
(appendix pp 10–11).
The proportion of patients with STEMI was lower in 
Sweden than in the UK (32% vs 40%). The distributions of 
age and sex were similar in the two countries (table 1). 
Swedish patients had more favourable risk profi les than 
UK patients for some factors (eg, lower prevalence of 
current smoking and higher systolic blood pressure at 
admission), but worse risk profi les for other factors (eg, 
higher prevalence of diabetes, heart failure, and 
cerebrovascular disease). Previous use of antiplatelet and 
β-blocker therapy was greater in Sweden, but use of statins 
on admission was lower (table 1).
Total reperfusion for STEMI was more common in the 
UK than in Sweden (77% vs 71%). Fibrinolysis was also 
more common in the UK (54% vs 12%), but primary PCI 
Sweden (n=119 786) UK (n=391 077)
Casemix
STEMI 38 432 (32·1%, 31·8–32·3) 157 418 (40·3%, 40·1–40·4)
Mean (SD) age (years) 71·2 (12·3) 69·5 (13·6)
Female 43 512 (36·3%, 36·1–36·6) 135 664 (34·8%, 34·7–34·9)
Median (IQR) AMI severity
Systolic blood pressure (mm Hg) 145 (125–165) 139 (120–158)
Heart rate (beats per min) 78 (65–93) 79 (66–94)
Troponin I (μg/L) 4·2 (0·8–18·0) 4·4 (0·8–21·7)
Troponin T (μg/L) 0·7 (0·2–2·3) 0·65 (0·2–2·3)
Risk factor
Current smoker 25 085 (23·3%, 23·0–23·5) 104 522 (29·5%, 29·3–29·6)
History of diabetes 26 992 (22·7%, 22·4–22·9) 65 458 (17·6%, 17·4–17·7)
History of hypertension 53 155 (45·2%, 44·9–45·5) 173 342 (47·3%, 47·2–47·5)
Cardiovascular disease history
Heart failure 10 859 (9·7%, 9·5–9·8) 18 944 (5·3%, 5·2–5·4)
Cardiac arrest before admission 1578 (1·3%, 1·3–1·4) 8478 (2·3%, 2·2–2·3)
Cerebrovascular disease 9816 (10·1%, 9·9–10·3) 30 091 (8·5%, 8·4–8·5)
Myocardial infarction 26 526 (22·4%, 22·1–22·6) 67 346 (18·3%, 18·1–18·4)
Prehospital treatment
Antiplatelet monotherapy 43 485 (36·6%, 36·3–36·9) 98 247 (26·4%, 26·3–26·6)
Antiplatelet dual therapy 4788 (4·0%, 3·9–4·1) 10 931 (2·9%, 2·9–3·0)
PCI 9475 (8·0%, 7·8–8·2) 19 473 (5·4%, 5·4–5·5)
CABG 9192 (7·7%, 7·6–7·9) 17 383 (4·8%, 4·8–4·9)
Hospital treatment
STEMI patients
Total reperfusion treatment 27 354 (71·2%, 70·7–71·6) 118 880 (76·6%, 76·4–76·8)
Prehospital fi brinolysis 1533 (4·1%, 3·9–4·4) 13 903 (9·3%, 9·2–9·5)
In-hospital fi brinolysis* 4539 (11·8%, 11·5–12·1) 84 112 (54·2%, 54·0–54·5)
Primary PCI 22 773 (59·3%, 58·8–59·8) 34 695 (22·4%, 22·2–22·6)
Median (IQR) delay from symptom to 
fi brinolysis (min)
177 (108–322) 150 (94–285)
Median (IQR) delay from symptom to 
primary PCI (min)
198 (129–365) 199 (140–328)
Non-STEMI and STEMI patients
Coronary intervention other than primary 
PCI
34 288 (28·6%, 28·4–28·9) 58 492 (17·3%, 17·2–17·5)
IV glycoprotein IIb/IIIa receptor inhibitors 24 993 (21·0%, 20·8–21·2) 28 389 (8·6%, 8·5–8·7)
Anticoagulants 87 271 (73·2%, 73·0–73·5) 28 3344 (83·0%, 82·9–83·1)
Median (IQR) duration of hospital stay (days) 5 (3–7) 6 (3–10)
Discharge medication
Antiplatelet monotherapy 30 409 (27%, 26·8–27·3) 103 218 (34·2%, 34·1–34·4)
Antiplatelet dual therapy 76 099 (67·6%, 67·3–67·9) 183 753 (60·9%, 60·8–61·1)
β blocker 99 779 (88·7%, 88·5–88·9) 231 505 (78·2%, 78–78·3)
ACE inhibitor or ARB 63 102 (56·2%, 55·9–56·5) 242 300 (82·3%, 82·2–82·5)
Statin 89 767 (79·7%, 79·5–79·9) 276 335 (92·8%, 92·7–92·9)
Values are number (%, 95% CI) unless stated otherwise. STEMI=ST-segment-elevation myocardial infarction. AMI=acute 
myocardial infarction. PCI=percutaneous coronary intervention. CABG=coronary artery bypass graft surgery. IV=intravenous. 
ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. *Prehospital and in-hospital fi brinolysis are not 
mutually exclusive.
Table 1: Casemix and treatment for patients with AMI in Sweden and the UK
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was notably more common in Sweden (59% vs 22%; 
table 1). The median delay from symptom onset to 
hospital admission was similar in the two countries. The 
median delay from symptom onset to primary PCI in 
STEMI patients was similar, but for fi brinolysis the delay 
was longer in Sweden (table 1). Overall, coronary 
interventions (other than primary PCI) and use of 
intravenous glycoprotein IIb/IIIa agents were higher in 
Sweden than in the UK. For patients who survived to 
hospital discharge, those in Sweden were more likely 
than those in the UK to be prescribed dual antiplatelet 
therapy or β blockers, but less likely to be prescribed ACE 
inhibitors or ARBs and statins (table 1).
In both countries the use of primary PCI to treat STEMI 
increased over time and use of fi brinolysis decreased 
(fi gure 2, appendix p 20). In 2004, almost all STEMI 
patients in the UK received fi brinolysis, but this decreased 
substantially over time and use of primary PCI reached the 
Swedish 2004 rate in 2009. Over time, the use of any 
antiplatelet medication at discharge was similar in the two 
countries. Use of dual antiplatelet therapy at discharge was 
initially low in the UK but increased over time and had 
exceeded that in Sweden by 2009 (appendix p 20). Use of 
β blockers at discharge was constantly higher in Sweden, 
whereas use of ACE inhibitors or ARBs and use of statins 
were higher in the UK (fi gure 2).
Cumulative 30-day mortality was higher in the UK than 
in Sweden (fi gure 3). When assessed according to 
troponin concentrations, acute infarct severity (heart rate 
and blood pressure at admission), age, sex, year of 
admission, smoking, and diabetes status, 30-day mortality 
in the UK remained consistently higher than that in 
Sweden (table 2). The strength and direction of casemix-
adjusted associations between 30-day mortality and age, 
year of admission, blood pressure, heart rate, diabetes 
status, history of cardiovascular disease, and previous 
revascularisation were similar in Sweden and the UK 
(appendix p 18). In-hospital mortality was also higher in 
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Figure 2: Use of reperfusion or fi brinolysis to treat STEMI and medication at discharge among all patients, by year
(A) Primary PCI and (B) fi brinolysis, including any given before admission or in hospital. (C) Any antiplatelet therapy and statin and (D) use of β blockers and ACEI or 
ARBs among all acute myocardial infarction patients who survived to discharge. STEMI=ST-segment-elevation myocardial infarction. PCI=percutaneous coronary 
intervention. ACEI=angiotensin-converting-enzyme inhibitor. ARB=angiotensin-receptor blocker.
Figure 3: Kaplan-Meier curves for cumulative mortality at 30 days after admission with acute myocardial 
infarction in Sweden and the UK
*Time of censoring or vital status at 30 days missing for 129 patients in the UK.
Number at risk
Sweden
UK
0 5 10 15 20 25
UK: 30-day risk of death 10·5%
(95% CI 10·4–10·6)
Sweden: 30-day risk of death 7·6%
(95% CI 7·4–7·7)
30
119 786
390 948
115 113
370 883
113 364
362 830
112 345
357 954
111 646
354 475
111 136
351 919
110 693
349 845
Time since admission (days)
0
2
4
6
8
10
Cu
m
ul
at
iv
e 
m
or
ta
lit
y 
fro
m
 a
ny
 ca
us
e 
(%
)
Articles
www.thelancet.com   Vol 383   April 12, 2014 1309
the UK (8·8%, 8·7–8·9) than in Sweden (5·8%, 5·7–5·9). 
In clinically important subgroups, in-hospital mortality 
was consistently higher in the UK than in Sweden 
(appendix p 21).
After standardisation with the Swedish casemix model, 
UK mortality was lower than the unadjusted, crude 
estimates (appendix p 22). After standardisation, the 
forecast mean 30-day mortality between 2004 and 2010 was 
7·7% (95% CI 7·3–8·2). If the same casemix was assumed 
in Sweden and the UK, the standardised mortality ratio 
was 1·37 (1·30–1·45), which corresponded to an estimated 
11 263 (9620–12 827) more deaths in the UK between 
2004 and 2010 than in Sweden. The greatest annual 
diff erence between countries in mortality was seen in 
2004, when the standardised mortality ratio was 1·47 
(1·38–1·58), but decreased signifi cantly over time to 1·20 
(1·12–1·29) in 2010 (fi gure 4). The propensity-matched 
analyses gave similar fi ndings (appendix p 15). We 
explored the extent to which mortality diff erences between 
countries might be explained by diff erences in medical 
care, by casemix standardisation and treatment in hospital 
and also by estimating what might have diff ered if the UK 
had the same level of use of primary PCI and β blockers 
as Sweden from 2004 onwards, assuming treatment 
benefi ts reported in randomised clinical trials. If the level 
of use of primary PCI and β blockers had been the same 
in the UK as in Sweden, we estimate the standardised 
mortality ratio would have reduced from 1·37 to 1·31 (95% 
CI 1·30–1·33; appendix pp 22, 24). When in-hospital 
treatments were included in addition to casemix, the 
standardised mortality ratio decreased from 1·37 to 1·21 
(1·15–1·29 appendix pp 22–23).
Discussion
We found greater mortality among patients with acute 
myocardial infarction in the UK than similar patients in 
Sweden. The diff erences in the care and outcomes of acute 
myocardial infarction are a cause for concern. Uptake of 
eff ective treatments, especially primary PCI to treat STEMI 
and β blockers at discharge, was slower in the UK than in 
Sweden. The greater cumulative 30-day mortality in the 
UK was much improved after standardisation with the 
Swedish casemix. This approach suggests that more than 
10 000 deaths at 30 days would have been prevented or 
delayed had UK patients experienced the care of their 
Swedish counterparts.
Several lines of evidence support the validity of 
comparing care and outcomes across these registries. 
First, by design we captured data on the whole system in 
both countries (all hospitals and consecutive patients) 
and have used common data defi nitions. That these data 
are comparable is supported by our fi nding that the 
associations between casemix variables and mortality 
were similar in the two countries. Second, the diagnosis 
of acute myocardial infarction was comparable, with 
troponin values and propensity to make a diagnosis being 
similar. Third, diff erences in 30-day mortality between 
countries were consistent within strata defi ned by 
troponin values and other clinically important subgroups.
The use of primary PCI to treat STEMI in the UK lagged 
behind that in Sweden; the rate in 2010 in the UK (53%) 
Number of deaths/patients 30-day mortality (%, 95% CI)
Sweden 
(n=119 786)
UK
(n=391 077)
Sweden 
(n=119 786)
UK
(n=391 077)
ST-segment elevation
STEMI 3248/37 937 17 681/15 7365 8·6% (8·3–8·8) 11·2% (11·1–11·4)
Non-STEMI 5923/80 724 23 828/23 3586 7·3% (7·2–7·5) 10·2% (10·1–10·3)
Severity of myocardial infarction
Troponin I (μg/L)
<5·0 1487/29 793 5994/80 991 5·0% (4·7–5·2) 7·4% (7·2–7·6)
5·0–9·9 484/6725 1670/17 524 7·2% (6·6–7·8) 9·5% (9·1–10·0)
10·0–20·0 487/6256 1560/16 342 7·8% (7·1–8·5) 9·5% (9·1–10·0)
≥20·0 1404/13 255 4630/40 765 10·6% (10·1–11·1) 11·4% (11·1–11·7)
Troponin T (μg/L)
<0·2 724/12 846 2382/30 756 5·6% (5·3–6·0) 7·7% (7·5–8·0)
0·2–0·5 598/10 263 2060/23 937 5·8% (5·4–6·3) 8·6% (8·3–9·0)
0·5–1·0 559/7963 1674/17 774 7·0% (6·5–7·6) 9·4% (9·0–9·9)
≥1·0 2453/22 921 6038/50 485 10·7% (10·3–11·1) 12·0% (11·7–12·2)
Admission systolic blood pressure (mm Hg)
<110 2279/9729 10 532/47 796 23·4% (22·6–24·3) 22·0% (21·7–22·4)
110–140 2882/31 750 13 331/123 072 9·1% (8·8–9·4) 10·8% (10·7–11)
≥140 2732/62 743 11 406/166 274 4·4% (4·2–4·5) 6·9% (6·7–7·0)
Admission heart rate (beats per min)
<90 4143/73 584 18 307/230 648 5·6% (5·5–5·8) 7·9% (7·8–8·0)
90–120 2760/24 235 12694/82674 11·4% (11–11·8) 15·4% (15·1–15·6)
≥120 1103/7933 4418/24 525 13·9% (13·2–14·7) 18·0% (17·5–18·5)
Demographic characteristics
Male 5069/75 406 22 549/25 4110 6·7% (6·5–6·9) 8·9% (8·8–9·0)
Female 4102/43 255 18 823/135 608 9·5% (9·2–9·8) 13·9% (13·7–14·1)
Age
<65 years 717/35 262 4487/142 392 2·0% (1·9–2·2) 3·2% (3·1–3·2)
65–75 years 1385/29 859 7651/94 442 4·6% (4·4–4·9) 8·1% (7·9–8·3)
75–85 years 3731/36 324 16 288/101 943 10·3% (10–10·6) 16·0% (15·8–16·2)
≥85 years 3338/17 216 13 083/52 174 19·4% (18·8–20) 25·1% (24·7–25·4)
Year of admission
2004 1803/18 294 7300/55 447 9·9% (9·4–10·3) 13·2% (12·9–13·4)
2005 1568/17 274 6842/54 421 9·1% (8·7–9·5) 12·6% (12·3–12·9)
2006 1368/16 865 5966/52 757 8·1% (7·7–8·5) 11·3% (11–11·6)
2007 1224/17 601 5547/53 276 7·0% (6·6–7·3) 10·4% (10·2–10·7)
2008 1145/16 647 5505/55 851 6·9% (6·5–7·3) 9·9% (9·6–10·1)
2009 1010/15 796 5237/58 479 6·4% (6–6·8) 9·0% (8·7–9·2)
2010 1053/16 184 5112/60 720 6·5% (6·1–6·9) 8·4% (8·2–8·6)
Risk factors
Diabetes 2657/26 769 8444/65 424 9·9% (9·6–10·3) 12·9% (12·7–13·2)
No diabetes 6371/91 275 29 647/307 409 7·0% (6·8–7·1) 9·6% (9·5–9·7)
Current smoker 1086/24 651 5765/104 503 4·4% (4·2–4·7) 5·5% (5·4–5·7)
Non-smoker 5939/82 205 26 463/249 814 7·2% (7–7·4) 10·6% (10·5–10·7)
STEMI=ST-segment-elevation myocardial infarction.
Table 2: 30-day mortality in patients with acute myocardial infarction in Sweden and the UK, by clinically 
relevant subgroups
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was similar to that in Sweden in 2005 (50%). Primary PCI 
was more eff ective than fi brinolysis in a meta-analysis,28 and 
this fi nding was refl ected in guideline recommendations 
in the USA in 2004,29 and in Europe in 2005.30 The UK did 
not have a national policy for primary PCI until October, 
2008,31 which could explain the rapid increase in the use of 
this treatment from 2008 onwards, but it took until 
2011–12 for rates to exceed 90%.32
The use of evidence-based secondary prevention showed 
a mixed pattern, with statin therapy and ACE inhibitors or 
ARBs being more commonly prescribed in the UK than in 
Sweden, whereas use of β blockers at discharge was more 
common in Sweden. β blockers have been reported to be 
effi  cacious for secondary prevention of acute myocardial 
infarction in randomised, controlled trials, and have been 
included in guideline recommendations for acute 
myocardial infarction in Europe33 and the USA34 since 
1996, but their use was not recommended in the UK until 
2001.35
Our fi ndings suggest that these diff erences in clinical 
care contributed to international diff erences in patients’ 
outcomes. The mortality gap between Sweden and the UK 
decreased over time, which is consistent with the 
narrowing gap between treatments. Application of 
Swedish rates of primary PCI and β blocker use to the UK 
population or inclusion of in-hospital treatments in the 
standardisation were associated separately with reduced 
diff erences in mortality between the two countries.
Other features of health care are not measured in these 
registries (eg, why particular patients do or do not receive 
particular types of care), and these features probably 
contribute to explaining the mortality gap. We show that 
improved understanding of selection processes in the two 
countries is needed (appendix p 23). Mortality might be 
aff ected by multiple unmeasured features of care, 
including doses, timing, adherence to drugs, diff erences 
in operator experience, shared and specialty care pathways, 
use of decision-support tools, and organisa tional culture.12
In all countries, patients, payers and policymakers could 
ask how outcomes in their health systems compare with 
our results. Policy initiatives are required to identify, 
understand, and reduce gaps between treatment use and 
outcomes in diff erent health systems. We suggest that 
progress towards this goal is achievable because the 
narrowing of the gap between mortality in Sweden and the 
UK indicates that diff erences are reversible. Between-
country comparisons of nationwide care and outcomes is a 
novel approach; most quality-outcome initiatives so far 
have been concentrated on within-country and within-
system metrics. For Sweden our results highlight the value 
of quality of sustained, system-wide initiatives to improve 
quality, including the public reporting of outcomes at 
hospital level. For the UK our results suggest the 
usefulness of learning from systems that seem to be 
performing better.1,2
Our study has several limitations. First, we cannot 
exclude the possibility that unmeasured features of 
casemix contributed to the diff erences in mortality. 
However, standardisation, stratifi cation, and analysis of 
propensity scores all reported similar results, which 
supports an actual and signifi cant diff erence between 
countries. Our casemix model is as comprehensive as the 
registries allow and included 17 variables in demography, 
acute myocardial infarction severity, risk factor, 
comorbidity, and prehospital treatment. Second, we could 
not assess the care received by patients who died before 
reaching hospital, although we believe this is unlikely to 
explain the higher mortality in the UK because the time 
from symptom onset to admission was similar to that in 
Figure 4: 30-day mortality of UK patients admitted in each study year, standardised according to the Swedish 
casemix model
p=0·01 for linear trend across years for the relative risks. AMI=acute myocardial infarction. 
Casemix- 
standardised
risk ratio (95% CI)
Number of 
UK AMI 
patients
Observed 
UK 30-day 
mortality (%)
Year
 2004
 2005
 2006
 2007
 2008
 2009
 2010
55 447
54 421
52 757
53 276
55 851
58 479
60 720
13·2
12·6
11·3
10·4
9·9
9·0
8·4
1·47 (1·38–1·58)
1·44 (1·35–1·54)
1·35 (1·26–1·45)
1·41 (1·31–1·51)
1·37 (1·28–1·48)
1·34 (1·24–1·45)
1·20 (1·12–1·29)
1·00·8 1·61·1 1·2 1·3 1·4 1·50·9
Mortality Sweden higher
Standardised relative risk
Mortality UK higher
Panel: Research in context
Systematic review
We searched Medline via PubMed with the medical subject headings “myocardial 
infarction”, “Outcome Assessment (Health Care)”, and “internationality” and identifi ed 
studies published in English from January, 1990 to September, 2013. Additional 
references from identifi ed studies, reviews, or relevant citations provided by experts were 
manually checked to supplement the literature searches. We identifi ed six closely relevant 
studies reporting substantial variation in the use and uptake of evidence-based medicine 
for care of acute myocardial infarction between countries.8–11,15,16 These studies, however, 
were based on selected samples of hospital patients in voluntary registries,8–10 cross-
sectional surveys,15 a clinical trial,16 or with only ST-segment-elevation acute myocardial 
infarction (STEMI)8–9,11 or non-STEMI.10 One study reported important between-countries 
diff erences in acute myocardial infarction mortality18 and the uptake of some evidence-
based medicine. Our search revealed no previous studies comparing quality of care 
between two countries with nationwide coverage and taking into account heterogeneity 
in patients’ casemix.
Interpretation
We found evidence of clinically important international diff erences in the uptake of eff ective 
treatments for and outcomes from AMI. 30-day mortality after AMI was higher among UK 
patients than among Swedish patients. Diff erences in mortality were not explained by 
diff erences in casemix, but were partly attributable to recorded diff erences in clinical care. 
International comparisons of care and outcome registries might yield important, actionable 
insights to guide health-care policy and clinical practice to improve the quality of health 
systems and prevent avoidable deaths from acute myocardial infarction.
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Sweden and diff erences in mortality became apparent 
after the fi rst day in hospital. Third, the registries do not 
capture all patients admitted with acute myocardial 
infarction and, in the UK, missed patients are likely to be 
older and less likely to be under the care of a cardiologist 
than patients recorded in the registry.36 Because the 
nationwide registries in Sweden have been established 
longer than in the UK, missed cases might be less frequent 
in Sweden, which suggests the actual diff erence in 
mortality could be wider. Fourth, the quality and 
completeness of data (in themselves markers of quality of 
care) might introduce bias in our casemix model. In 
sensitivity analyses, however, estimates for the associations 
between casemix variables and 30-day mortality based on 
complete case analysis verifi ed the results from multiple 
imputed data (appendix pp 18–19).
Our comparison of international outcomes suggests a 
novel research agenda (panel).37 First, additional patient-
level health-care factors that are not measured might 
explain diff erences between countries. International 
harmonisation of detailed measures of quality of care in 
clinical registries, such as pathways of care, is needed. 
Second, at the national level, whether initiatives, such as 
national policies, fi nancial incentives, organisation, and 
leadership, aff ect the delivery of care is unclear. Third, 
outcomes should be compared with those in other 
countries, such as France, Hungary, Poland, and the USA, 
through assessment of national, albeit voluntary, registries. 
Fourth, with linkage to national electronic health records, 
there are opportunities to extend comparisons to include 
ambulatory care before and after admission for heart 
attack, non-fatal events, and longer-term outcomes.38
We found clinically important diff erences in the care and 
outcomes of patients with acute myocardial infarction in 
Sweden and the UK. International comparisons of care 
and outcome registries might inform new research and 
policy initiatives to improve the quality of health systems.
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